Skip to main content
Figure 4 | Molecular Medicine

Figure 4

From: ARA 290 Improves Symptoms in Patients with Sarcoidosis-Associated Small Nerve Fiber Loss and Increases Corneal Nerve Fiber Density

Figure 4

Evaluation of efficacy using the SFNSL shows a sustained improvement in the ARA 290 treatment group compared with placebo. (A) One week after the end of dosing, a larger percentage of patients in the ARA 290 group attained a specified range of score improvement over a broad range of responses. (B) This difference was largely maintained at the end of the 16 wks of follow-up.

Back to article page

Molecular Medicine

ISSN: 1528-3658